Nicholas Corcoran Sells 2,966 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Nicholas Corcoran sold 2,966 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $412,629.92. Following the completion of the sale, the insider owned 29,831 shares of the company’s stock, valued at $4,150,088.72. The trade was a 9.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

TransMedics Group Stock Down 0.2%

TMDX stock traded down $0.34 during trading on Wednesday, reaching $147.66. 701,764 shares of the stock were exchanged, compared to its average volume of 830,019. The firm’s 50 day moving average is $134.97 and its 200 day moving average is $126.78. The firm has a market cap of $5.06 billion, a P/E ratio of 30.13 and a beta of 1.98. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. TransMedics Group, Inc. has a twelve month low of $62.07 and a twelve month high of $156.00.

Analyst Ratings Changes

TMDX has been the topic of a number of analyst reports. Morgan Stanley upped their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Finally, Needham & Company LLC upped their price objective on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $150.67.

Institutional Investors Weigh In On TransMedics Group

Institutional investors have recently made changes to their positions in the stock. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after acquiring an additional 206 shares during the period. Salomon & Ludwin LLC purchased a new stake in TransMedics Group during the 3rd quarter worth about $28,000. Harvest Fund Management Co. Ltd purchased a new stake in TransMedics Group during the 3rd quarter worth about $29,000. Allworth Financial LP boosted its stake in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the period. Finally, Optiver Holding B.V. grew its holdings in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after buying an additional 191 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.